(131)I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma

Nanoscale Research Letters
Haiyan Wang, Weizhong Sheng

Abstract

Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, (131)I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-(131)I) to evaluate their cell uptake activity, in vivo blood circulation, and biodistribution. The FA-PLP-(131)I nanoparticles had a spherical morphology with great stability, a narrow size distribution (165.6 and 181.2 nm), and -22.1 mV in average zeta potential. Confocal laser scanning microscopy indicated that the targeting molecule FA promotes PLP-(131)I uptake by melanoma B16F10 cells, which was further confirmed by the cell incorporation rate via (131)I activity detection as measured by a gamma counter. FA-PLP-(131)I without PTX (FA-PL-(131)I) shows minor cytotoxicity, good biocompatibility, while FA-PLP-(131)I was demonstrated to have efficient cell viability suppression compared to free PTX and PLP-(131)I. Following intravenous injection, the blood circulation half-life of free PTX (t 1/2 = 5.4 ± 0.23 h) was prolonged to 18.5 ± 0.5 h by FA-PLP-(131)I. Through FA targeting, the tumor uptake of FA-P...Continue Reading

References

Apr 1, 2005·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Perihan Unak, Berkan Cetinkaya
Aug 15, 2008·Cancer Research·Zhuang LiuHongjie Dai
Mar 23, 2010·Advanced Drug Delivery Reviews·Vladimir Torchilin
Jan 1, 2009·OncoTargets and Therapy·Francesco Di CostanzoFederica Di Costanzo
Aug 28, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabienne DanhierVéronique Préat
Apr 20, 2011·Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques·Moorthi ChidambaramK Kathiresan
Feb 23, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fabienne DanhierVéronique Préat
Mar 13, 2014·International Journal of Pharmaceutics·Daniela SmejkalováVladimír Velebný
Dec 3, 2014·Cancer Letters·Tommaso AzzaritoStefano Fais
Jan 30, 2015·Journal of the American Chemical Society·Fuwu ZhangKaren L Wooley
Mar 31, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Edgar Pérez-Herrero, Alberto Fernández-Medarde
Aug 27, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melissa A WilsonKatherine L Nathanson
Apr 30, 2016·Nature Reviews. Cancer·A Hunter Shain, Boris C Bastian
Nov 9, 2016·OncoTargets and Therapy·Kazutoshi KomiyaNaoko Sueoka-Aragane

❮ Previous
Next ❯

Citations

Aug 11, 2018·Journal of Cancer Research and Clinical Oncology·Harshita MishraSushama Talegaonkar
Sep 18, 2020·Advances in Colloid and Interface Science·Aoxue ZhangShuyu Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
dynamic light scattering
nanoprecipitation
fluorescence imaging

Related Concepts

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.